"Timolol in essential hypertension" a preliminary report.

A study of a new beta-adrenergic blocking drug TIMOLOL (Blocadren) in the treatment of essential hypertension has been undertaken. Twelve hypertensive patients previously undiagnosed and untreated were studied. Results with a twice a day dose of the drug showed a satisfactory fall in systolic and diastolic pressures in all but one patient, who was withdrawn from the trial because of excessive bradycardia. Apart from bradycardia, no serious side effects were observed in the patients. Observation over longer period is advocated to determine the place of Timolol in our antihypertensive armamentorium.